Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
Inhalative administration of vasoactive intestinal peptide (VIP) is a promising approach for the treatment of severe lung diseases. However, the clinical use of VIP is limited by the fact that the peptide is prone to rapid degradation mechanisms and proteolytic digestion. Accordingly, VIP exhibits a very short period of activity in the lung. To overcome this problem, we have designed a liposomal drug delivery system for VIP and characterized it in terms of its potential to protect VIP from enzymatic cleavage. The proteolytic conditions of the lung, the target site of aerosolic administered VIP, were mimicked by bronchoalveolar lavage fluid (BALF), a lung surfactant solution, obtained by fiberoptic bronchoscopy. Thus, the stability of VIP was assessed by its resistance to enzymatic degradation in BALF, using a combination of high pressure liquid chromatography with mass spectrometry. We found that free VIP was rapidly digested, whereas liposomal-associated VIP remained intact. By fluorescence spectroscopic techniques using fluorescent-labelled VIP we got strong indications that the tight association of VIP with the lipid membrane is only minimally affected upon incubation with BALF. Loading capacity and stability of EtCy3-VIP loaded liposomes were measured by fluorescence fluctuation spectroscopy. Finally, the protective properties of the liposomes were also expressed in the maintained biological activity of the peptide incubated with BALF.
Institute of Biophysics and Nanosystems Research, Austrian Academy of Sciences, Graz, Austria.
Brigitte
B
Stark
Fritz
F
Andreae
Wilhelm
W
Mosgoeller
Michael
M
Edetsberger
Erwin
E
Gaubitzer
Gottfried
G
Koehler
Ruth
R
Prassl
D000280:Administration, Inhalation; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D002626:Chemistry, Pharmaceutical; D004355:Drug Stability; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D008081:Liposomes; D008168:Lung / Q000201:enzymology*; D008297:Male; D010316:Particle Size; D010447:Peptide Hydrolases / Q000378:metabolism*; D011651:Pulmonary Artery / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D019141:Respiratory System Agents / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D013997:Time Factors; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology
D008055:Lipids; D008081:Liposomes; D019141:Respiratory System Agents; D014665:Vasodilator Agents; D014660:Vasoactive Intestinal Peptide; D010447:Peptide Hydrolases